In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: onr:"swepub:oai:DiVA.org:oru-84961" > In vitro activity o...

1 av 1
Föregående post
Nästa post
Till träfflistan

Jensen, Jørgen SkovDepartment of Bacteria, Parasites and Fungi, Research Unit for Reproductive Tract Microbiology, Statens Serum Institut, Copenhagen, Denmark (författare)

In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium

Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

2020-06-18
Taylor & Francis,2020
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:oru-84961
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-84961URI
https://doi.org/10.1080/22221751.2020.1775498DOI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Funding Agencies:GlaxoSmithKlineFederal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under OTA Agreement HHSO100201300011C
Mycoplasma genitalium has developed resistance to first-line azithromycin and second-line moxifloxacin. Third-line pristinamycin is only 75% effective. Gepotidacin, a novel triazaacenaphthylene topoisomerase II inhibitor, blocks bacterial DNA replication. We determined thein vitroactivity of gepotidacin alone and in combination with doxycycline against a diverse collection of Mycoplasma genitalium isolates (n = 54).Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined by a Vero-cell culture method. Macrolide resistance was present in 31 (57%) isolates, fluoroquinolone resistance in 18 (33%) isolates, and 17 (31%) had dual resistance. Synergy testing was performed for gepotidacin and doxycycline by checkerboard analysis for two macrolide- and two dual-resistant isolates.Gepotidacin was active against all 54 M. genitalium isolates with median and modal MICs of 0.125 mg/L and MIC(90)of 0.25 mg/L (range <= 0.016-0.5 mg/L). No difference in gepotidacin MIC between macrolide-resistant and -susceptible isolates (p = 0.24) or between fluoroquinolone-, dual-resistant and -susceptible isolates (p = 0.2) was demonstrated. Gepotidacin MBCs were available for 44 M. genitalium isolates with median MIC of 0.064 mg/L and median MBC of 0.125 mg/L. All isolates had <= 4-fold difference between MIC and MBC, suggesting bactericidal effect for gepotidacin. Checkerboard analysis indicated synergistic effect for gepotidacin in combination with doxycycline [fractional inhibitory concentration index (sigma FICI) of 0.5] for two isolates and additive/indifference (sigma FICI at 0.62 and 0.75) for two isolates.Gepotidacin warrants further evaluation in clinical treatment trials for M. genitalium. Combination therapy with doxycycline should be clinically studied to assess effect and potential protection against development and/or spread of gepotidacin resistance.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper Immunologi inom det medicinska området hsv//swe
MEDICAL AND HEALTH SCIENCES Basic Medicine Immunology in the medical area hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper Mikrobiologi inom det medicinska området hsv//swe
MEDICAL AND HEALTH SCIENCES Basic Medicine Microbiology in the medical area hsv//eng
Mycoplasma genitalium
antimicrobial resistance
gepotidacin
in-vitro susceptibility testing
combination therapy

Biuppslag (personer, institutioner, konferenser, titlar ...)

Nørgaard, ChristinaDepartment of Bacteria, Parasites and Fungi, Research Unit for Reproductive Tract Microbiology, Statens Serum Institut, Copenhagen, Denmark (författare)
Scangarella-Oman, NicoleGlaxoSmithKline, Collegeville Pennsylvania, USA (författare)
Unemo, Magnus,1970-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län(Swepub:oru)muo (författare)
Department of Bacteria, Parasites and Fungi, Research Unit for Reproductive Tract Microbiology, Statens Serum Institut, Copenhagen, DenmarkGlaxoSmithKline, Collegeville Pennsylvania, USA (creator_code:org_t)

Sammanhörande titlar

Ingår i:Emerging Microbes & Infections: Taylor & Francis9:1, s. 1388-13922222-1751

Internetlänk

Hitta via bibliotek

Emerging Microbes & Infections (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Jensen, Jørgen S ...; Nørgaard, Christ ...; Scangarella-Oman ...; Unemo, Magnus, 1 ...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Medicinska och f ...; och Immunologi inom ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Medicinska och f ...; och Mikrobiologi ino ...

Artiklar i publikationen: Emerging Microbe ...

Av lärosätet: Örebro universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se